Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics has started a Phase 1/2 clinical trial evaluating HTI-501 (rHuCAT-L) in women suffering from moderate to severe edematous fibrosclerotic panniculopathy.
Subscribe to our email newsletter
The Phase 1 dose escalation portion of the trial aims to investigate a single injection of different HTI-501 formulations into dimpled lesions of the skin followed by a Phase 2 portion of the trial where multiple lesions will be targeted with the optimal dose and formulation.
Principal investigator of the trial Francisco Perez said if HTI-501 proves to be pharmacologically active and well tolerated, it could represent a completely novel approach to the treatment of cellulite.